SEARCH

SEARCH BY CITATION

References

  • 1
    de Lange T. Telomeres and senescence: ending the debate. Science 1998; 279: 3345.
  • 2
    Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5: 4749.
  • 3
    Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM, Bjorkholm M, Teh BT, Nordenskjold M, Xu D. Molecular Characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003; 63: 17437.
  • 4
    Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002; 2: 25765.
  • 5
    Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 45860.
  • 6
    Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 116470.
  • 7
    Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 238899.
  • 8
    Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 13215.
  • 9
    Langford LA, Piatyszek MA, Xu R, Schold SC,Jr, Shay JW. Telomerase activity in human brain tumours. Lancet 1995; 346: 12678.
  • 10
    Falchetti ML, Pallini R, Larocca LM, Verna R, D'Ambrosio E. Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 1999; 52: 2346.
  • 11
    Chong EY, Lam PY, Poon WS, Ng HK. Telomerase expression in gliomas including the nonastrocytic tumors. Hum Pathol 1998; 29: 599603.
  • 12
    Harada K, Kurisu K, Tahara H, Tahara E, Ide T, Tahara E. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 2000; 93: 61825.
  • 13
    Sugita Y, Nakashima A, Kato S, Sakata K, Morimatsu M, Shigemori M. Telomerase activity in gliomas with the use of non-radioisotopic and semi-quantitative procedure for terminal repeat amplification protocol. Oncol Rep 2000; 7: 108792.
  • 14
    Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361: 8368.
  • 15
    Falchetti ML, Pallini R, D'Ambrosio E, Pierconti F, Martini M, Cimino-Reale G, Verna R, Maira G, Larocca LM. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int J Cancer 2000; 88: 895901.
  • 16
    Kleinschmidt-DeMasters BK, Hashizumi TL, Sze CI, Lillehei KO, Shroyer AL, Shroyer KR. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling. J Clin Pathol 1998; 51: 28493.
  • 17
    Weil RJ, Wu YY, Vortmeyer AO, Moon YW, Delgado RM, Fuller BG, Lonser RR, Remaley AT, Zhuang Z. Telomerase activity in microdissected human gliomas. Mod Pathol 1999; 12: 416.
  • 18
    De Stasio G, Casalbore P, Pallini R, Gilbert B, Sanita F, Ciotti MT, Rosi G, Festinesi A, Larocca LM, Rinelli A, Perret D, Mogk DW, et al. Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 2001; 61: 42727.
  • 19
    Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74: 46586.
  • 20
    Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 2437.
  • 21
    Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, Possenti R, Levi A. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 2000; 21: 199219.
  • 22
    Falchetti ML, Pierconti F, Casalbore P, Maggiano N, Levi A, Larocca LM, Pallini R. Glioblastoma induces vascular endothelial cells to express telomerase in vitro. Cancer Res 2003; 63: 37504.
  • 23
    Falchetti ML, Levi A, Molinari P, Verna R, D'Ambrosio E. Increased sensitivity and reproducibility of TRAP assay by avoiding direct primers interaction. Nucleic Acids Res 1998; 26: 8623.
  • 24
    Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 2634.
  • 25
    Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 8349.
  • 26
    Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 13346.
  • 27
    Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001; 8: 82734.
  • 28
    Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003; 9: 3794800.
  • 29
    Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG, Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005; 41: 62434.
  • 30
    Ozawa T, Gryaznov SM, Hu LH, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-Oncol 2004; 6: 21826.
  • 31
    Herbert B-S, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999; 96: 1472681.
  • 32
    Shammas MA, Simmonds CG, Corey DR, Reis RJS. Telomerase inhibition by peptide nucleic acids reverses the “immortality” of transformed cells. Oncogene 1999; 18: 6191200.
  • 33
    Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR, Blackburn EH. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 2004; 64: 483340.
  • 34
    Li S, Crothers J, Haqq CM, Blackburn EH. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 2005; 280: 2370917.
  • 35
    Chang S, DePinho RA. Telomerase extracurricular activities. Proc Natl Acad Sci USA 2002; 99: 125202.
  • 36
    Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL, Blasco MA. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001; 20: 261930.
  • 37
    Artandi SE, Alson S, Tietze MK, Sharpless NE, Ye S, Greenberg RA, Castrillon DH, Horner JW, Weiler SR, Carrasco RD, DePinho RA. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 2002; 99: 81916.
  • 38
    Pallini R, Pierconti F, Falchetti ML, D'Angelo D, Fernandez E, Maira G, D'Ambrosio E, Larocca LM. Evidence for telomerase involvement in the angiogenesis of astrocytic tumors. Expression of human telomerase reverse transcriptase (hTERT) mRNA by vascular endothelial cells. J Neurosurg 2001; 94: 96171.
  • 39
    Franco S, Segura I, Riese HH, Blasco MA. Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Res 2002; 62: 5529.
  • 40
    Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 116377.
  • 41
    Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6: 11023.
  • 42
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 24957.
  • 43
    Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116: 101322.
  • 44
    Brown CK, Khodarev NN, Yu J, Moo-Young T, Labay E, Darga TE, Posner MC, Weichselbaum RR, Mauceri HJ. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett 2004; 565: 16770.
  • 45
    Yang J, Nagavarapu U, Relloma K, Sjaastad MD, Moss WC, Passaniti A, Herron GS. Telomerized human microvasculature is functional in vivo. Nature Biotechnol 2001; 19: 21924.
  • 46
    Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 73952.
  • 47
    Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 2005; 53: 9971002.
  • 48
    von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002; 27: 33944.
  • 49
    Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 2002; 9: 101729.
  • 50
    Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002; 2: 61626.
  • 51
    Sonoda Y, Ozawa T, Hirose Y, Aldape KD, MaMahon M, Berger MS, Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001; 61: 495660.
  • 52
    Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res 2001; 61: 355660.
  • 53
    Evans RJ, Wyllie FS, Wynford-Thomas D, Kipling D, Jones CJ. A P53-dependent, telomere-independent proliferative life span barrier in human astrocytes consistent with the molecular genetics of glioma development. Cancer Res 2003; 63: 485461.
  • 54
    Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 52738.
  • 55
    Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001; 61: 66748.
  • 56
    Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen H-J. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002; 8: 111722.